TriForce® Peripheral Crossing Set Commercially Available

Companies in the Global Vaccine Delivery Devices Market Expedite Product Innovations to Stay at Forefront in the Market in the COVID-19 Pandemic

Fact.MR has recently compiled a report, which reveals that the vaccine delivery devices market globally is projected to reflect an impressive CAGR over the forecast period, 2017 – 2022.

Sirtex Medical and BlackSwan Vascular Report 1st Patient Enrolled in Pivotal LAVA Study

The LAVA Study, which stands for Liquid Embolization of Arterial Hemorrhages in Peripheral Vasculature, is a prospective, multicenter single-arm study of 113 subjects at 20 investigational sites in the U.S.

The TriForce Peripheral Crossing Set is designed to be percutaneously introduced into blood vessels and support a wire guide while performing a peripheral intervention. This device is also intended for injection of radiopaque contrast media for the purpose of angiography. TriForce is offered in two lengths and four configurations, which means physicians have several product options to treat blocked or restricted vessels in a variety of locations in the body.

Mark Breedlove, vice president of the Cook Medical Vascular division, said, “We are excited to have this tool available for our physicians to treat complex peripheral vascular disease.”

spot_img

DON'T MISS

Related Articles